Dstock,
I really believe that most of the facilities being developed for vaccine production are working on mass produced vaccines, not personalized vaccines. We are a very different animal than the vaccines being manufactured to protect billions of people around the world from the likes of flu, covid, RSV, etc. No doubt some vaccines are being developed that are intended for cancer, but they too aren't personalized. Those vaccines are trying to target certain cancers, but are still intended to be manufactured in quantities needed for patients with that specific cancer, and of course they're not as specifically targeted to one patients cancer, but rather in general with people with that specific form of cancer.
I believe that many cleanroom facilities exist worldwide that potentially could be equipped with EDEN units that have the other capabilities needed for supporting it, including cryogenic support. I'm not saying that distributed processing will be used, if it were to be, I still believe every EDEN unit would be tied to computers controlled by NWBO, but manufacturing probably will be centralized. I can't say if it would ultimately be one or two locations, or dozens all under NWBO control in countries throughout the world.
It's not impossible that that newly built vaccine facilities couldn't be equipped with hundreds, even thousands of EDEN units, but I don't believe that it's what they're being built for. I suspect that CRL will eventually play a major role in providing DCVax-L and initially it will be at their Memphis facility, but other facilities they operate could also be involved as demand for DCVax-L increases worldwide.
Gary
AI
Market Data 
Markets 
